Plexiform architecture in gastrointestinal stromal tumors is not restricted to succinate dehydrogenase-deficient cases by Giustiniani, Maria Cristina et al.
Contents lists available at ScienceDirect
Human Pathology: Case Reports
journal homepage: www.elsevier.com/locate/ehpc
Case Report
Plexiform architecture in gastrointestinal stromal tumors is not restricted to
succinate dehydrogenase-deficient cases
Maria Cristina Giustiniania, Valerio Papab, Maurizio Martinia, Federica Castria, Tonia Cencia,
Sergio Alfierib, Riccardo Riccia,⁎
a Department of Pathology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli", Rome, Italy
bDepartment of Surgery, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli", Rome, Italy
A R T I C L E I N F O
Keywords:
Gastrointestinal stromal tumor
Platelet-derived growth factor receptor alpha
Multinodular architecture
Plexiform architecture
Succinate dehydrogenase
A B S T R A C T
Accumulating evidence reveals the heterogeneous features of gastrointestinal stromal tumors (GISTs), primarily
distinguished by their various molecular triggers defining well characterized subgroups. The identification of the
pathogenetic group a given GIST belongs to, in combination with the currently adopted GIST prognosticators, is
pivotal for the correct management of GIST patients. Epidemiological, anatomical and morphological features
are more or less strictly associated with the various possible GIST molecular pathogenesis; therefore, they can
concur to addressing molecular analysis or even influence the identification of GIST subsets by themselves. This
is particularly true in a cost/benefit perspective aimed at cutting the expenses of pathology labs. Under these
circumstances, a correct classical pathological analysis still appears a fundamental step to achieve an optimal
GIST characterization.
We herein report a gastric epithelioid PDGFRA-mutant GIST displaying the multinodular/plexiform archi-
tecture distinctive of succinate dehydrogenase (SDH)-deficient GISTs. Immunohistochemistry and molecular
analysis led to the correct tumor characterization. The reported case constitutes a valuable contribution to GIST
pathology in that it demonstrates that multinodular/plexiform architecture is not restricted to SDH-deficient
GISTs, but can be found also in PDGFRA-mutant ones; this is an event to be aware of, given the predilection for
gastric location and epithelioid morphology shared by these two GIST subgroups, only the latter of which in-
cludes imatinib-sensitive cases.
1. Introduction
Gastrointestinal stromal tumors (GISTs) are the most common me-
senchymal tumors of the gastrointestinal tract. Differences in molecular
pathogenesis characterize heterogeneous GIST subgroups [1], whose
identification, in combination with the currently adopted prog-
nosticators, is pivotal for the correct management of GIST patients [2].
Clinical and morphological features, variously associated with the di-
verse GIST molecular defects, can help in identifying GIST subsets, ei-
ther directly or by contributing to orient molecular analysis, especially
in a bona fide cost/benefit perspective aimed at cutting the outlay of
pathology labs. Therefore, a correct “classical” pathological diagnosis
appears still fundamental for an optimal GIST characterization.
Two of the known pathogenetic GIST subgroups are characterized
by a predilection for both gastric location and epithelioid cytology: that
mutated in the platelet-derived growth factor receptor alpha (PDGFRA)
gene and that featuring succinate dehydrogenase (SDH) deficiency [3].
Of note, part of the former tumors are amenable to the molecular tar-
geted therapy employing imatinib, whereas the latters are usually im-
atinib-resistant [4, 5]. We herein report a p.Val561Asp exon 12
PDGFRA-mutant gastric epithelioid GIST displaying a multinodular/
plexiform architecture which had previously undergone incomplete
surgical resection that, thanks to its genotype, could be treated by ad-
juvant imatinib after the second surgery. Our findings show that a
multinodular/plexiform pattern, considered distinctive of SDH-defi-
cient cases [5], can be found also in PDGFRA-mutant GISTs, con-
tributing to the knowledge of the basic pathology of these tumors.
2. Materials and methods
2.1. Patient
A 42-year-old man presented with abdominal discomfort. Physical
and routine laboratory tests were unremarkable. Eight months earlier,
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the patient had undergone laparoscopic resection of a gastric GIST in
another hospital. Six months after this surgical procedure, contrast-
enhanced abdominal CT scan and endoscopic ultrasound showed a 5 cm
gastric tumor, originating from the site of the previous resection in the
wall of the greater curvature, bulging into the gastric lumen, consistent
with gastric GIST. Thus, eight months after the first surgery, the patient
underwent a gastric wedge resection in our hospital. Informed written
consent for this study was obtained from the individual tested. The
procedures followed were in accordance with the Helsinki declaration
of 1975, as revised in 1983.
2.2. Histology and immunohistochemistry
Sections from formalin-fixed, paraffin-embedded specimens were
stained with hematoxylin/eosin. For immunohistochemistry, the fol-
lowing antibodies were used: CD117 (DAKO, Glostrup, Denmark, rabbit
polyclonal, 1:400), DOG1 (Spring Bioscience, Pleasanton, CA, USA,
rabbit polyclonal, 1:100), and SDHB (21A11, ABCAM, Cambridge, MA,
1:1000). Specific pre-immune sera or isotype-specific unrelated pri-
mary antibodies were used for the control stainings. For CD117 and
DOG1, the detection system consisted of DAKO visualization reagent
(dextran polymer conjugated with horseradish peroxidase and goat
anti-rabbit and anti-mouse immunoglobulins), for DOG1 preceded by
antigen retrieval (10 min in 0.01M citrate buffer, pH6, microwave at
750W), with 3,3′- diaminobenzidine chromogen solution. For SDHB,
the Leica BondMax autostainer (Leica Microsystems, Bannockburn, IL)
was employed utilizing the BondMax avidin biotin free polymer-based
detection system preceded by heat-induced epitope retrieval with Leica
retrieval solution (alkaline buffer), using diaminobenzine as the chro-
mogen. Sections were counterstained with hematoxylin.
2.3. Genetic analysis
DNA was obtained from slides cut from paraffin-embedded tissues.
These were treated twice with xylene and then washed with ethanol.
DNA was extracted using the QIAamp tissue kit (Qiagen, Hilden,
Germany) according to the manufacturer's protocol. Pathologic areas,
containing at least 70% disease-specific tissue, were analyzed.
Mutational analysis was also performed in normal tissue (gastric wall
and mucosa). KIT (exons 9, 11, 13 and 17) and PDGFRA (exons 12, 14
and 18) genes were amplified using the same primers and PCR condi-
tions described elsewhere [6, 7]. Briefly, DNA (100–200 ng) of normal
and pathological areas was amplified in a mixture containing 1× PCR
buffer [20mM TRIS (pH 8.3), 50 mMKCl, 1.5mM MgCl2], dNTPs
(200mM each), primers (20 pM each), and 0.5 U Taq polymerase pla-
tinum (Invitrogen, Milan, Italy) in a final volume of 25 l. PCR condi-
tions were: an initial denaturation of 95 °C for 8min, followed by
35 cycles of 95 °C for 40 s, 55 °C for 40 s and 72 °C for 40 s. After vi-
sualization onto agarose gel, PCR products were treated with ExoSAP-IT
(USB Corp, Cleve- land, Ohio) following the manufacturer's protocol,
amplified with BigDye Terminator version 3.1 cycle sequencing kit
(Applied Biosystems) using forward and reverse primers, and sequenced
with an ABI PRISM 3100-Avant Genetic Ana- lyzer (Applied Biosys-
tems). Water was used as negative control.
3. Results
3.1. Pathology
An intramural, 33 mm tumor was resected together with an 85mm
portion of gastric wall. The lesion was centered in the muscularis pro-
pria and showed a plexiform architecture, consisting of multiple jux-
taposed nodules (Fig. 1A, B); these nodules were made up of epithelioid
cells (Fig. 1C); CD117 immunostaining was only patchy and mostly
faint (Fig. 1D; occasional nuclear pleomorphism was evident); SDHB
positivity was intense and diffuse (Fig. 1E); DOG1 was positive (not
shown). Mitotic activity reached 3/5mm2. These features were con-
sistent with gastric epithelioid GIST, SDH-proficient.
3.2. Genetic analysis
A point mutation (c.1682 T > A) determining a Val for Asp sub-
stitution at 561 (p.Val561Asp) in PDGFRA gene (Fig. 2) was found in
tumor, but not in normal tissue (not shown).
4. Discussion
We herein report a PDGFRA-mutant, SDH-proficient GIST simu-
lating a SDH-deficient one because of its morphological features.
After the seminal discovery of both KIT mutations and KIT expres-
sion in GISTs in 1998 [8, 9], pivotal for both their reliable identification
and effective molecular-targeted treatment, these tumors revealed a
rather heterogeneous group of neoplasms, driven by several possible,
mutually exclusive molecular triggers [1]. The various pathogenetic
GIST subsets differ in epidemiology, pathology and clinical features.
Two GIST subgroups are distinguishable because of their propensity for
epithelioid cytology and gastric location: PDGFRA-mutant and SDH-
deficient ones. The former tumors, although prevailing in the stomach,
can also occur in the bowel, are often negative or only patchy and
mildly positive for CD117, and can respond to imatinib depending on
the type of PDGFRA mutation [4, 10]. Conversely, SDH-deficient GISTs
are virtually exclusively gastric, stain diffusely and intensely for CD117,
and are almost invariably imatinib-resistant; additionally, they pecu-
liarly show a multinodular, plexiform architecture and tend to affect
young people, mostly manifesting before the age of 40 years; finally,
current GIST risk classifications fail to predict their clinical behavior [5,
11, 12].
The herein reported PDGFRA-mutant GIST presented with deceiving
features, simulating a SDH-deficient GIST. In fact, it displayed a mul-
tinodular, plexiform architecture (Fig. 1A, B), considered distinctive of
the latter GIST type [5]; also compatible with SDH-deficiency were its
gastric location and epithelioid cytology (Fig. 1C), and the relatively
young age of the patient. However, the detected patchy and mostly
weak CD117 positivity (Fig. 1D) was not typical of SDH-deficient GISTs,
being rather suggestive of a concealed mutation of PDGFRA [10, 13].
SDHB intense and diffuse immunostaining confirmed the presence of a
functional SDHB enzymatic complex (Fig. 1E). Finally, molecular ana-
lysis revealed a point mutation (c.1682 T > A) determining a Val for
Asp substitution at 561 (p.Val561Asp) in PDGFRA exon 12 (Fig. 2).
To the best of our knowledge, only one multinodular/plexiform
PDGFRA-mutant GIST has been signaled so far [14]. Unlike the case
reported herein, that GIST displayed a prominent myxoid matrix, a
feature consistent with the “myxoid epithelioid” subtype of PDGFRA-
mutant GIST [15] which, combined with the multinodular architecture
present in that particular case, simulated a plexiform fibromyxoma [16]
rather than a SDH-deficient GIST.
The multinodular, plexiform morphology of the GIST we report is
likely to have played a role in the incompleteness of the surgical re-
section the patient had previously undergone. Similarly, surgery is
often only apparently curative in SDH-deficient GISTs, typically plexi-
form in architecture; however, under the latter circumstances, the
propensity to lymph node metastases and the frequent presence of a
syndromic setting determined by a systemic SDH dysfunction often
contribute to surgical failures [5]. With regard to the case reported
herein, the detection of a wild-type PDGFRA in normal tissue ruled out
the possibility that the multiple tumor nodules found in the gastric wall
represented multiple GISTs in the setting of a germline PDGFRA mu-
tation.
Considering the above-mentioned previous incomplete tumor re-
section, an adjuvant therapy with imatinib has been initiated in the
reported case. The detection of a Val for Asp substitution at 561
(p.Val561Asp) in PDGFRA has revealed decisive for allowing this
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therapeutic choice.
5. Conclusions
The herein reported case constitutes a relevant contribution to GIST
pathology, proving that a multinodular/plexiform architecture is not
restricted to SDH-deficient GISTs, but can be found also in PDGFRA-
mutant ones. Additionally, it underlines once more the necessity of full
genotyping for achieving an exhaustive GIST characterization, in-
dependently of the detected clinical and morphologic features, as spe-
cific of a given GIST pathogenetic subset as these might be [17, 18].
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